stacking up

Houston rise in the ranks of the top emerging ecosystems in the world

According to a new report, Houston is among the top emerging ecosystems. Photo by Zview/Getty Images

If you need evidence that Houston's startup ecosystem is flourishing, look no further than a new report from Startup Genome and the Global Entrepreneurship Network.

This year's Global Startup Ecosystem Report, released September 22, places Houston at No. 19 among the world's top 100 emerging startup ecosystems. Furthermore, it puts Houston at No. 4 among the top regional challengers in North America. Last year's report lumped Houston with other emerging startup ecosystems in the 31-to-40 ranking range.

Mumbai, India, appears at No. 1 among the world's top 100 emerging startup ecosystems this year, while Miami lands at No. 1 among the top regional challengers in North America.

According to Houston Exponential, the city's startup ecosystem "is experiencing a growth spurt that appears to show no signs of abating."

Case in point: Houston startups raised more than $1 billion in the first six months of 2021, surpassing all annual totals from previous years. In 2020, Houston startups reaped a record-high $753 million in venture capital.

"Venture capital invested in Houston startups has nearly quadrupled since 2016," according to a recent Houston Exponential report. "The sustained level of progress we've seen in startup formation and growth over the past four years shows that Houston has what it takes to build a vibrant, healthy innovation economy with an emphasis on equity."

Collectively, the health care and information technology sectors accounted for nearly 60 percent of Houston's VC deals in the first half of 2021, the report says.

Another sign of the expansion of Houston's startup ecosystem: the rising number of workspaces, incubators, and accelerators designed to foster startups.

"These key institutions create density and drive collisions among founders, investors, and talent, significantly increasing the rate of startup formation and growth," according to the Greater Houston Partnership.

Those institutions include The Ion entrepreneurial hub, the Greentown Labs climate-tech incubator, and the DivInc startup accelerator. All are new arrivals on the Houston startup scene.

"DivInc is about broadening the startup ecosystem by making it more authentically diverse, equitable, and inclusive of underrepresented entrepreneurs," Preston James II, CEO of DivInc, said in April. "When we, as a community, do this successfully, we optimize our opportunities for economic GDP growth, we can help reduce racial/gender wealth divide, and drive greater innovation."

Elsewhere in Texas, Austin ranks 20th among the leading startup ecosystems in the Global Startup Ecosystem Report, down from No. 19 last year, and Dallas repeats its 31st-place tie. Silicon Valley tops the global list.

The report says North America represents half of the top 30 ecosystems in the world.

"Entrepreneurs, policymakers, and community leaders in North America have been working hard to build inclusive innovation ecosystems that are engines of economic growth and job creation for all," JF Gauthier, founder and CEO of Startup Genome, says in a news release.

San Francisco-based Startup Genome is a research and advisory firm specializing in startup ecosystems.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted